Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.
McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, Linnane B, Kirwan L, Rea D, O'Regan P, Semple T, Saunders C, Tiddens HAWM, McKone E, Davies JC; RECOVER Study Group. McNally P, et al. Among authors: kirwan l. Am J Respir Crit Care Med. 2023 Nov 1;208(9):917-929. doi: 10.1164/rccm.202308-1317OC. Am J Respir Crit Care Med. 2023. PMID: 37703083 Clinical Trial.
Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L, Fletcher G, Harrington M, Jeleniewska P, Zhou S, Casserly B, Gallagher CG, Greally P, Gunaratnam C, Herzig M, Linnane B, McElvaney NG, McKone EF, McNally P, Mullane D, Ní Chróinín M, O'Mahony M, Plant BJ, Jackson AD. Kirwan L, et al. Ann Am Thorac Soc. 2019 Feb;16(2):209-216. doi: 10.1513/AnnalsATS.201802-149OC. Ann Am Thorac Soc. 2019. PMID: 30427731
Telehealth in Cystic Fibrosis. A systematic review incorporating a novel scoring system and expert weighting to identify a 'top 10 manuscripts' to inform future best practices implementation.
Vagg T, Shanthikumar S, Ibrahim H, O'Regan P, Chapman WW, Kirwan L, Ranganathan SC, Plant BJ. Vagg T, et al. Among authors: kirwan l. J Cyst Fibros. 2023 Jul;22(4):598-606. doi: 10.1016/j.jcf.2023.05.012. Epub 2023 May 23. J Cyst Fibros. 2023. PMID: 37230808 Free PMC article. Review.
The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting.
McNally P, Linnane B, Williamson M, Elnazir B, Short C, Saunders C, Kirwan L, David R, Kemner-Van de Corput MPC, Tiddens HAWM, Davies JC, Cox DW. McNally P, et al. Among authors: kirwan l. Respir Res. 2023 Aug 11;24(1):199. doi: 10.1186/s12931-023-02497-0. Respir Res. 2023. PMID: 37568199 Free PMC article.
Impact of the common MTHFR 677C→T polymorphism on blood pressure in adulthood and role of riboflavin in modifying the genetic risk of hypertension: evidence from the JINGO project.
Ward M, Hughes CF, Strain JJ, Reilly R, Cunningham C, Molloy AM, Horigan G, Casey M, McCarroll K, O'Kane M, Gibney MJ, Flynn A, Walton J, McNulty BA, McCann A, Kirwan L, Scott JM, McNulty H. Ward M, et al. Among authors: kirwan l. BMC Med. 2020 Nov 11;18(1):318. doi: 10.1186/s12916-020-01780-x. BMC Med. 2020. PMID: 33172445 Free PMC article.
75 results